PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.00
Negative P/E while Biotechnology median is -5.94. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.39
P/B 1.25-1.5x Biotechnology median of 3.01. Guy Spier would scrutinize if premium reflects better asset utilization.
-18.41
Negative FCF while Biotechnology median P/FCF is -22.82. Seth Klarman would investigate cash flow improvement potential.
-18.51
Negative operating cash flow while Biotechnology median P/OCF is -21.95. Seth Klarman would investigate operational improvement potential.
4.39
Fair value ratio 1.25-1.5x Biotechnology median of 3.02. Guy Spier would scrutinize if premium reflects durable advantages.
-5.00%
Negative earnings while Biotechnology median yield is -2.82%. Seth Klarman would investigate path to profitability.
-5.43%
Negative FCF while Biotechnology median yield is -2.49%. Seth Klarman would investigate cash flow improvement potential.